Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting
Yasuo Kubota, Xiaorong Gu, Laila Terkawi, Juraj Bodo, Bartlomiej Przychodzen, Hussein Awada, Nakisha D Williams, Carmelo Gurnari, Naomi Kawashima, Mai Aly, Arda Durmaz, Minako Mori, Ben Ponvilawan, Tariq Kewan, Waled Bahaj, Manja Meggendorfer, Babal K. Jha, Valeria Visconte, Heesun J. Rogers, Torsten Haferlach, Jaroslaw P. Maciejewski
Abstract
Abstract PHF6 mutations ( PHF6 MT ) are identified in various myeloid neoplasms (MN). However, little is known about the precise function and consequences of PHF6 in MN. Here we show three main findings in our comprehensive genomic and proteomic study. Firstly, we show a different pattern of genes correlating with PHF6 MT in male and female cases. When analyzing male and female cases separately, in only male cases, RUNX1 and U2AF1 are co-mutated with PHF6 . In contrast, female cases reveal co-occurrence of ASXL1 mutations and X-chromosome deletions with PHF6 MT . Next, proteomics analysis reveals a direct interaction between PHF6 and RUNX1. Both proteins co-localize in active enhancer regions that define the context of lineage differentiation. Finally, we demonstrate a negative prognostic role of PHF6 MT , especially in association with RUNX1 . The negative effects on survival are additive as PHF6 MT cases with RUNX1 mutations have worse outcomes when compared to cases carrying single mutation or wild-type.